Anbogen Therapeutics partners with Tokyo University on ABT-301 research
August 25, 2026 | 09:52
Oncology company Anbogen Therapeutics signed a research agreement with the University of Tokyo on 24 August 2026 to test cancer drug ABT-301 across multiple tumor indications.
Mobile Version